MolMed
Italian biotechnology company focused on cancer-related cell and gene therapies.
Last updated August 26, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
MolMed was an Italian biotechnology company established in Milan in 1996 as a joint venture between Science Park Raf and Boehringer Mannheim. Its early business operated primarily as a contract development and manufacturing organization, providing services to companies working on gene-therapy and cell-therapy programs. After Boehringer Mannheim was acquired by Roche and Roche subsequently sold its interest, MolMed developed a more independent research and product-development model. In 2000, it began concentrating on proprietary therapeutic programs rather than relying principally on contracted work. The company was closely associated with the San Raffaele biomedical and scientific ecosystem in Milan. In 2001, MolMed entered an agreement with San Raffaele Hospital that gave it an option to license inventions developed at the hospital in cancer and HIV gene- and cell-therapy fields. In 2002, it acquired and incorporated Genera S.p.A., a research company of the San Raffaele Scientific Institute. These arrangements gave MolMed access to an academic and clinical research base while it built an industrial platform for advanced therapies. MolMed's principal strategic focus became oncology. Its programs included genetically modified cellular therapies, including the TK technology later commercialized as Zalmoxis, and NGR-hTNF, an investigational biologic designed to target tumor-associated blood vessels. The company worked across research, process development, manufacturing, clinical validation, and regulatory preparation. Its facilities were located at the San Raffaele Biomedical Science Park in Milan, with an additional operational site at OpenZone in Bresso. The company raised capital from Italian private investors during its development. Fininvest, Herule Finance, and La Leonardo Finanziaria joined the shareholder base through a 2004 capital increase, while further capital increases followed in 2006 and 2007. MolMed listed on the Italian stock market in 2008 through an initial public offering that placed approximately 25% of its shares and raised €56 million before expenses. A 2010 rights issue raised a further €58 million before expenses and doubled the number of outstanding shares. A major commercial and scientific milestone came with the development of TK, a donor-derived cell-therapy approach intended to support haploidentical hematopoietic stem-cell transplantation. The European Commission granted conditional marketing authorization in August 2016 under the brand name Zalmoxis for use as an adjunct treatment in adult patients with high-risk blood cancers undergoing haploidentical transplantation. MolMed had also been involved in the early development of Strimvelis, a gene-therapy product later associated with GlaxoSmithKline. MolMed ceased to exist as an independent listed company after AGC, the Japanese materials and life-sciences group, launched a takeover bid in 2020. Fininvest, then the reference shareholder, announced that it would participate in the offer. Following completion of the transaction, MolMed's shares were delisted, and the business became part of AGC Biologics. The MolMed name therefore primarily represents the company's independent pre-acquisition history in Italian cell- and gene-therapy development.
History
MolMed was founded in Milan in 1996 by Claudio Bordignon as a joint venture between Science Park Raf and Boehringer Mannheim. The company initially worked as a contract organization for businesses developing gene- and cell-therapy products. During its first years, Boehringer Mannheim was acquired by Roche, after which Roche sold its stake in MolMed to the venture-capital fund EDCP. In 2000, MolMed changed direction and began developing proprietary therapeutic products. The company built a close relationship with San Raffaele Hospital and the San Raffaele Scientific Institute. A 2001 agreement granted MolMed an option to license certain hospital-generated inventions in cancer and HIV gene- and cell-therapy fields. In 2002, MolMed acquired and incorporated Genera S.p.A., a research company of the San Raffaele Scientific Institute. The relationship supported the company's transition from a service provider into a biotechnology developer with its own clinical programs. MolMed raised significant private and public capital as it expanded. Fininvest, Herule Finance, and La Leonardo Finanziaria entered its shareholder base through a €20 million capital increase in 2004. Additional increases followed in 2006 and 2007. In 2008, MolMed completed an initial public offering on the Italian stock market, offering approximately 25% of its shares and raising €56 million before expenses. A 2010 rights issue raised €58 million before expenses and resulted in one new share being issued for each existing share. Its research portfolio centered on oncology and advanced therapies. The best-known program was TK, a genetically modified cell-therapy approach intended to make partially compatible donor transplantation possible for patients requiring hematopoietic stem-cell treatment. The product was developed under the commercial name Zalmoxis. On 24 June 2016, the Committee for Medicinal Products for Human Use issued a positive opinion on conditional authorization, and the European Commission granted conditional marketing authorization on 18 August 2016 for use alongside haploidentical transplantation in adults with leukemia and other high-risk hematological malignancies. Another major program was NGR-hTNF, an investigational anti-cancer agent designed to target tumor blood vessels. It advanced to a phase III study in malignant pleural mesothelioma and phase II studies in several other cancers, including colorectal, liver, small-cell and non-small-cell lung, ovarian, and soft-tissue sarcoma indications. MolMed also participated in the early development of Strimvelis, a gene-therapy product later associated with GlaxoSmithKline. MolMed's main facilities were located in the San Raffaele Biomedical Science Park in Milan, with an operational site at OpenZone in Bresso. In March 2020, AGC launched a full takeover bid at €0.518 per share. Fininvest, which held approximately 23.13% at the time, announced its intention to accept the offer, as did H-Invest. The offer was followed by the delisting of MolMed's shares. By the end of the transaction, the company had become part of AGC Biologics, ending MolMed's existence as an independent listed biotechnology company.
- 2020
AGC takeover and delisting
[1]AGC launches a takeover bid for MolMed, after which the company's shares are delisted and the business becomes part of AGC Biologics.
- 2016
Zalmoxis receives European conditional authorization
[1]The European Commission grants conditional marketing authorization to Zalmoxis, the commercial name for MolMed's TK cell therapy.
- 2015
Collaboration related to Strimvelis
[1]MolMed partners with GlaxoSmithKline in connection with GSK's acquisition and development of Strimvelis, a gene-therapy product with which MolMed had been involved during early development.
- 2010
Rights issue
[1]The company completes a €58 million rights issue before expenses, doubling the number of issued shares.
- 2008
Italian stock-market listing
[1]MolMed completes an IPO representing approximately 25% of its shares and raises €56 million before expenses.
- 2004
Private-investor capital increase
[1]Fininvest, Herule Finance, and La Leonardo Finanziaria join the shareholder base through a €20 million capital increase.
- 2002
Acquisition of Genera
[1]MolMed acquires and incorporates Genera S.p.A., a research company of the San Raffaele Scientific Institute.
- 2001
San Raffaele licensing agreement
[1]MolMed signs an agreement giving it an option to license relevant gene- and cell-therapy inventions from San Raffaele Hospital.
- 2000
Shift toward proprietary product development
[1]MolMed changes its business model and begins developing its own cell- and gene-therapy products.
- 1996
MolMed is founded in Milan
[1]Claudio Bordignon establishes MolMed as a joint venture between Science Park Raf and Boehringer Mannheim.
Products and positioning
Specialist biotechnology company focused on translating cell- and gene-therapy research into clinical and commercial oncology products, while also providing advanced-therapy development and manufacturing capabilities.
Cell therapy · 2016
Zalmoxis
Zalmoxis was the commercial name for MolMed's TK cell-therapy technology. It was designed for use after haploidentical hematopoietic stem-cell transplantation, using genetically modified donor lymphocytes to support immune reconstitution while incorporating a mechanism intended to help manage graft-versus-host disease. The European Commission granted it conditional marketing authorization in 2016 as an adjunct treatment for adult patients with leukemia and other high-risk blood cancers.
Cell-therapy technology
TK
TK was MolMed's underlying donor-cell technology for partially compatible bone-marrow or hematopoietic stem-cell transplantation. The approach sought to extend transplantation options where a fully matched donor was unavailable and formed the scientific basis of Zalmoxis. Its development combined genetic modification, cell processing, transplantation medicine, and immune-control objectives.
Oncology biologic
NGR-hTNF
NGR-hTNF was an investigational anti-cancer agent intended to target the blood vessels that support tumor growth. MolMed advanced the program into phase III clinical testing for malignant pleural mesothelioma and phase II studies across colorectal, liver, small-cell and non-small-cell lung, ovarian, and soft-tissue sarcoma indications. It remained a development-stage product rather than an established commercial medicine in the cited material.
Gene-therapy program · 2016
Strimvelis development services and collaboration
MolMed participated in the early development of Strimvelis, a gene-therapy product later associated with GlaxoSmithKline. The relationship illustrates MolMed's role not only as a proprietary product developer but also as a technical and development partner for advanced-therapy programs originating outside its own core portfolio.
Brand decisions
2020
Acceptance of AGC takeoverM&ABackground
AGC launched a full takeover bid while Fininvest was MolMed's reference shareholder.
Action taken
Fininvest announced its intention to participate in the offer priced at €0.518 per share; the transaction was subsequently completed.
Aftermath
MolMed's shares were delisted and the company became part of AGC Biologics.
Takeover offer price. €0.518 per share (2020 takeover bid)
2008
Initial public offeringOtherBackground
MolMed required public capital to support research, development, manufacturing, and clinical validation of advanced therapies.
Action taken
The company listed on the Italian stock market, offering approximately 25% of its shares.
Aftermath
The IPO raised €56 million before expenses and gave MolMed access to public-market financing.
IPO proceeds. €56 million before expenses (2008 IPO)
2000
Move from contract services to proprietary therapiesStrategyBackground
MolMed had initially operated mainly as a contract organization supporting other companies' gene- and cell-therapy projects.
Action taken
The company changed its business model and began developing its own therapeutic products and clinical programs.
Aftermath
The change established the oncology-focused biotechnology model that defined MolMed before its acquisition by AGC.
Recent events
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/molmed · Editorial policy · How profiles are compiled